Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative drugs operate by mimicking the physiological actions of GLP-1, a hormone released by the gut in response to food. By activating GLP-1 receptors in the pancreas, these compounds increase insulin release and inhibit glucag

The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a alike therapeutic goal – improving glycemic control and promoting considerable weight reduction – they exhibit intriguing contrasts in